Articles tagged "Kidney transplantation"

2017 American Transplant Congress
The Outcome of Kidney Grafts from Living Donors with Pyelo-Ureteric Junction Dysfunction.
C. Gledhill-Flynn, H. Ali, A. Ahmed.
Royal Preston Hospital, Preston, United Kingdom; Royal Preston Hospital, Preston, United Kingdom; Royal Preston Hospital, Preston, United Kingdom
Introduction: There is a wide gap between number of patients seeking renal transplants and potential kidney donors. Living kidney donation seems a reasonable source to…
2017 American Transplant Congress
Comparing Renal Function Recovery and Long Term Outcomes in Recipients of Standard and Expanded Criteria Donor Kidney Transplants.
S. Sandal, M. Cantarovich, S. Paraskevas, N. Almaghrawi, P. Chaudhury, J. Tchervenkov.
McGill University Health Center, Montreal, Canada
Several donor and recipient characteristics are associated with adverse kidney transplantation (KT) outcomes. Our group has previously shown that based on the donor's terminal creatinine,…
2017 American Transplant Congress
18 Month Analysis of the Impact of the New Kidney Allocation System on Deceased Donor Kidney Utilization at the Donor Service Area Level.
W. Ally, K. Brayman, A. Agarwal.
University of Virginia, Charlottesville, VA
In December 2014, UNOS implemented broad sweeping changes in the Kidney Allocation System (KAS). Recently, UNOS reported that key goals of the new policy have…
2017 American Transplant Congress
Biological Interplay Between Circulating HLA-sp Alloreactive Memory B-Cells and Long-Lived Plasma Cells in Kidney Transplant Patients Undergoing Chronic ABMR.
S. Luque,² M. Lúcia,⁴ M. Jarque,² E. Crespo,² E. Melilli,¹ J. Martorell,³ J. Cruzado,^1,2 J. Torras,^1,2 J. Grinyó,^1,2 O. Bestard.^1,2
¹Kidney Transplant Unit, Bellvitge University Hospital, Barcelona, Spain; ²Experimental Nephrology Laboratory, IDIBELL, Barcelona, Spain; ³Immunogenetics Laboratory, Hospital Clínic, Barcelona, Spain; ⁴Transplant Immunology, School of Medicine, Stanford
Alloreactive humoral responses are one of the main causes of immune-mediated allograft injury in kidney transplantation. Different biological compartments are involved in the generation and…
2017 American Transplant Congress
Shared Epitopes Contribute to Accumulation of Highly Sensitized Patients in Kidney Paired Donation Program.
S. Stepkowski, B. Mierzejewska, C. Baum, D. Bekbolsynov, R. Brunner, J. Kopke, S. Rees, M. Rees.
University of Toledo, Toledo, OH
Introduction: Kidney Paired Donation (KPD) programs suffer from the accumulation of highly sensitized patients. We evaluated the sensitization patterns in our KPD program-by comparison of…
2017 American Transplant Congress
Pre-Transplant Evaluation of KSORT^SM to Assess Risk for Rejection in Highly Sensitized Patients.
S. Nandoe,¹ S. Roedder,³ S. Hsieh,¹ T. Sigdel,¹ P. Lindner,⁴ J. Ekberg,⁴ J. Alberu,⁵ F. Vincenti,¹ M. Sarwal.¹
¹UCSF, San Francisco, CA; ²Immucor, Norcross, GA; ³Gothenburg University, Gothenburg, Sweden; ⁴Salvador Zubiran, Mexico City, Mexico
Study purpose: To investigate the kSORTSM molecular expression assay for immune risk assessment in renal transplant (tx) recipients prior to tx for correlation of pre-tx…
2017 American Transplant Congress
A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection.
G. de Graav,¹ C. Baan,¹ M. Clahsen-van Groningen,² R. Kraaijeveld,¹ M. Dieterich,¹ W. Verschoor,¹ D. Roelen,³ M. Cadogan,¹ J. van de Wetering,¹ J. van Rosmalen,⁴ W. Weimar,¹ D. Hesselink.¹
¹Internal Medicine, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ²Pathology, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ³Immunohematology and Blood Transfusion, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ⁴Biostatistics, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands
Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, has been associated with a higher acute rejection risk than ciclosporin. We sought to identify a biomarker…
2017 American Transplant Congress
Kidney Injury Molecule-1 Mitigates Tissue Damage from Transplant Renal Ischemia Reperfusion Injury.
J. Lee,^1,2 X. Zhang,² A. Haig,³ D. Lian,² P. Anderson,² R. Navaratnam,² L. Gunaratnam.^1,2
¹Department of Microbiology and Immunology, Western University, London, ON, Canada; ²Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, ON, Canada; ³Department of Pathology, Western University, London, ON, Canada
Ischemia reperfusion injury (IRI) at the time of organ harvesting is unavoidable, may cause delayed renal graft function, and is associated with premature graft loss.…
2017 American Transplant Congress
Circulating Donor-Specific Anti-HLA Antibodies Accelerate the Progression of Interstitial Fibrosis in Kidney Allografts.
C. Gosset, D. Viglietti, M. Rabant, E. Pillebout, A. Bouquegneau, J. Taupin, D. Glotz, C. Legendre, J. Duong Van-Huyen, A. Loupy, C. Lefaucheur.
Paris Translational Research Center for Organ Transplantation, Paris, France
Interstitial fibrosis represents a major cause of kidney allograft failure. Addressing the causes of accelerated ageing of kidney allografts represents an important challenge to improve…
2017 American Transplant Congress
Belatacept for Chronic Antibody-Mediated Rejection in Kidney Transplantation.
D. Kumar,¹ G. Gupta,¹ J. Reeve,² P. Sanghi,¹ S. Bobba,¹ M. Levy,¹ C. Bhati,¹ P. Kimball,¹ H. Fattah,¹ A. King,¹ H. Massey,¹ P. Halloran.²
¹Virginia Commonwealth University, Richmond; ²Alberta Transplant Applied Genomics Center, Edmonton, Canada
Background: Chronic antibody mediated rejection (cAMR) is a major cause of long-term kidney transplant (KT) loss. Antibody or immune cell depletional therapies have unclear efficacy…